Peptide receptor radionuclide therapy of neuroendocrine tumours

Tessa Brabander; Jaap Teunissen; Casper van Eijck; Gaston Franssen; R.A. Feelders; W.W. de Herder; Dik Kwekkeboom

doi:10.1016/j.beem.2015.10.005

Peptide receptor radionuclide therapy of neuroendocrine tumours

Tessa Brabander, Jaap Teunissen, Casper van Eijck, Gaston Franssen, R.A. Feelders, W.W. de Herder, Dik Kwekkeboom

Research output: Contribution to journal › Article › Academic › peer-review

52 Citations (Scopus)

Abstract

In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an infusion of somatostatin analogues linked to radionuclides like Yttrium-90 or Lutetium-177. Objective response rates are reported in 15-35%. Response rates may vary between type of tumour and radionuclide. Besides the objective response rate, overall survival and progression free survival increase significantly. Also, the quality of life improves as well. Serious side-affects are rare. PRRT is usually well tolerated, also in patients with extensive metastasised disease. Recent studies combined PRRT with other types of therapies. Unfortunately no randomised trials comparing these strategies are available. In the future, more research is needed to evaluate the best therapy combinations or sequence of therapies. (C) 2015 Elsevier Ltd. All rights reserved.

Original language	Undefined/Unknown
Pages (from-to)	103-114
Number of pages	12
Journal	Best Practice & Research Clinical Endocrinology & Metabolism
Volume	30
Issue number	1
DOIs	https://doi.org/10.1016/j.beem.2015.10.005
Publication status	Published - 2016

Research programs

EMC MM-01-39-01
EMC MM-03-47-02-A
EMC MM-04-47-07

Access to Document

10.1016/j.beem.2015.10.005

Cite this

@article{e9405a67d88e4f6d8e6eb12fad29135f,

title = "Peptide receptor radionuclide therapy of neuroendocrine tumours",

abstract = "In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an infusion of somatostatin analogues linked to radionuclides like Yttrium-90 or Lutetium-177. Objective response rates are reported in 15-35%. Response rates may vary between type of tumour and radionuclide. Besides the objective response rate, overall survival and progression free survival increase significantly. Also, the quality of life improves as well. Serious side-affects are rare. PRRT is usually well tolerated, also in patients with extensive metastasised disease. Recent studies combined PRRT with other types of therapies. Unfortunately no randomised trials comparing these strategies are available. In the future, more research is needed to evaluate the best therapy combinations or sequence of therapies. (C) 2015 Elsevier Ltd. All rights reserved.",

author = "Tessa Brabander and Jaap Teunissen and {van Eijck}, Casper and Gaston Franssen and R.A. Feelders and {de Herder}, W.W. and Dik Kwekkeboom",

year = "2016",

doi = "10.1016/j.beem.2015.10.005",

language = "Undefined/Unknown",

volume = "30",

pages = "103--114",

journal = "Best Practice & Research Clinical Endocrinology & Metabolism",

issn = "1521-690X",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Peptide receptor radionuclide therapy of neuroendocrine tumours

AU - Brabander, Tessa

AU - Teunissen, Jaap

AU - van Eijck, Casper

AU - Franssen, Gaston

AU - Feelders, R.A.

AU - de Herder, W.W.

AU - Kwekkeboom, Dik

PY - 2016

Y1 - 2016

N2 - In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an infusion of somatostatin analogues linked to radionuclides like Yttrium-90 or Lutetium-177. Objective response rates are reported in 15-35%. Response rates may vary between type of tumour and radionuclide. Besides the objective response rate, overall survival and progression free survival increase significantly. Also, the quality of life improves as well. Serious side-affects are rare. PRRT is usually well tolerated, also in patients with extensive metastasised disease. Recent studies combined PRRT with other types of therapies. Unfortunately no randomised trials comparing these strategies are available. In the future, more research is needed to evaluate the best therapy combinations or sequence of therapies. (C) 2015 Elsevier Ltd. All rights reserved.

AB - In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an infusion of somatostatin analogues linked to radionuclides like Yttrium-90 or Lutetium-177. Objective response rates are reported in 15-35%. Response rates may vary between type of tumour and radionuclide. Besides the objective response rate, overall survival and progression free survival increase significantly. Also, the quality of life improves as well. Serious side-affects are rare. PRRT is usually well tolerated, also in patients with extensive metastasised disease. Recent studies combined PRRT with other types of therapies. Unfortunately no randomised trials comparing these strategies are available. In the future, more research is needed to evaluate the best therapy combinations or sequence of therapies. (C) 2015 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.beem.2015.10.005

DO - 10.1016/j.beem.2015.10.005

M3 - Article

C2 - 26971847

SN - 1521-690X

VL - 30

SP - 103

EP - 114

JO - Best Practice & Research Clinical Endocrinology & Metabolism

JF - Best Practice & Research Clinical Endocrinology & Metabolism

IS - 1

ER -